Cevostamab

Roche to present over 40 abstracts on nine blood disorders at ASH 2024, highlighting long-term follow-up data for Polivy, Lunsumio, and Columvi, and new investigational combinations. Key findings include durable remissions and positive trends in overall survival for DLBCL, long-lasting remissions and immune recovery for FL and DLBCL, and potential benefits of subcutaneous Lunsumio. Patient-reported outcomes support Columvi's benefits in DLBCL. Roche continues to innovate in hematology with a broad portfolio and pipeline.

Roche to present over 40 abstracts on nine blood disorders at the 66th ASH Annual Meeting, highlighting long-term follow-up data for Polivy®, Lunsumio®, and Columvi®, and new combination data, reinforcing commitment to advancing lymphoma patient outcomes.

Genentech presents key studies on Polivy, Lunsumio, Columvi, Venclexta, Hemlibra, and PiaSky at medical conferences, highlighting efficacy and safety profiles of these medicines in treating various blood cancers and hemophilia A.